Zura Bio falls on $125 mln stock sale

Zura Bio

25/02/2026 12:30

** Zura Bio's ZURA.O shares down 5.4% before the bell to $6.33 after $125 mln follow-on prices

** Biotech firm says sold 20 mln shares, including pre-funded warrants to buy 1.8 mln shares, at $6.25

** Offering price represents 6.6% discount to stock's last close

** It intends to use net offering proceeds for working capital, advance its pipeline, and general purposes, per the prospectus

** Co says its lead product candidate, tibulizumab, being evaluated in mid-stage studies for autoimmune conditions hidradenitis suppurativa and systemic sclerosis

** Leerink, Piper Sandler and Cantor Fitzgerald joint bookrunners for offering

** Henderson, Nevada-headquartered co has ~73.7 mln shares outstanding

** Through Tues, ZURA shares up ~28% YTD. They closed at $1.28 a year ago

** All 8 analysts covering the stock are bullish including 4 "strong buy" ratings; median PT $15, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))